Low Molecular Weight Heparin (LMWH) has several advantages over other heparin such as longer and more predictable activity than Unfractionated Heparin (UFH) and can be self-administrated at home via subcutaneous injection, reducing or eliminating hospital stays, thereby no regular blood monitoring required. Furthermore, heparins do not cross the placenta or harm the fetus, so they are the preferred anticoagulants for pregnant women who experience or who are at heightened risk of – blood clots. These advantages make LMWH as the most preferred heparin in inhibiting clotting factors.
Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1491
Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.
Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.
Increasing Introduction of Biosimilar LMWH Anticoagulants Globally is Expected to Aid in the Market Growth
LMWH usage is expected to increase over the forecast period, due to a number of other non-anticoagulant properties. These include anti-tumor, anti-inflammatory, and anti-proliferative actions (in pathologies such as nephrotic syndrome and Alzheimer’s disease). The patents of LMWHs have now expired. However, the market potential for LMWHs is witnessing growth, owing to increasing use in a number of Western European countries and emerging economies and its potential indications, such as thromboprophylaxis, Venous thromboembolism (VTE), anticoagulation treatment during pregnancy, among others. Enoxaparin is the bestselling LMWH worldwide. Therefore, pharmaceutical companies in many countries are focused on producing generic forms of LMWH.
Key players operating in the low molecular weight heparin market include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.